Allergan (AGN) 87.58 0.52

Allergan, Inc.
(AGN) 87.58 0.52

Last Trade:	87.57	Day Range:	87.43 - 87.97
Trade Time:	11:02AM	52wk Range:	68.03 - 90.00
Prev. Close:	87.05	Market Cap:	26.71B
Open:	87.45	Div Yield:	0.23
Volume:	299439	PE:	290
EPS:	3.01

The Latest On AGN

UPDATE: Morgan Stanley Raises Allergan's PT 2/8/12 9:15am

Morgan Stanley Maintains Allergan at Overweight, Raises PT from $90 to $98 2/8/12 8:45am

UPDATE: Deutsche Bank Lowers Target on Allergan to $95 2/3/12 7:51am

Best Specialty Pharma Stocks Picked by UBS 1/20/12 6:27pm

ETF Showdown: Fun With Pharma 12/30/11 4:10pm

Notable Call Options Activity in Allergan 12/13/11 2:09pm

Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms 12/7/11 11:24am

Piper Jaffray Maintains Neutral Rating and $87 PT on Allergan 12/1/11 7:16am

Disclosure Insight Maintains Medium Risk Rating on Allergan 11/17/11 7:02am

Health Canada Approves BOTOX as Prophylactic Treatment for Chronic Migraine 11/14/11 9:09am

ExonHit Extends Strategic Collaboration with Allergan 11/2/11 5:54am

A Look at The New DRGS ETN 10/31/11 12:34pm

UPDATE: Morgan Stanley Raises Allergan's PT 2/8/12

Morgan Stanley Maintains Allergan at Overweight, Raises PT from $90 to $98 2/8/12

UPDATE: Deutsche Bank Lowers Target on Allergan to $95 2/3/12

Best Specialty Pharma Stocks Picked by UBS 1/20/12

ETF Showdown: Fun With Pharma 12/30/11

Notable Call Options Activity in Allergan 12/13/11

Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms 12/7/11

Piper Jaffray Maintains Neutral Rating and $87 PT on Allergan 12/1/11

Disclosure Insight Maintains Medium Risk Rating on Allergan 11/17/11

Health Canada Approves BOTOX as Prophylactic Treatment for Chronic Migraine 11/14/11

ExonHit Extends Strategic Collaboration with Allergan 11/2/11

A Look at The New DRGS ETN 10/31/11

Best Specialty Pharma Stocks Picked by UBS 1/20/12

ETF Showdown: Fun With Pharma 12/30/11

Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms 12/7/11

A Look at The New DRGS ETN 10/31/11

Allergan Earnings Preview: Analysts Expect Higher EPS, Revenue 10/25/11

News Summary for August 4, 2011 8/4/11

Earnings Expectations for the Week of August 1 7/31/11

Earnings Preview: Allergan's EPS, Revenue Expected to Rise 7/29/11

US Stock Futures Up As Investors Await Earnings Reports 2/2/11

Mad Money Lightning Round OT: Cramer Is A Buyer Of BBY (GLD, EGO, SLW, BIDU, GOOG, BBY, AGN, SMT, GSK, RFMD, AMAT) 11/17/10

Calls Purchased on Allergan, Inc. (AGN) 11/11/10

Market Roundup (AAPL, IBM, STX, PETS, AGN, HAL) 10/18/10

UPDATE: Morgan Stanley Raises Allergan's PT 2/8/12

Morgan Stanley Maintains Allergan at Overweight, Raises PT from $90 to $98 2/8/12

UPDATE: Deutsche Bank Lowers Target on Allergan to $95 2/3/12

Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms 12/7/11

Piper Jaffray Maintains Neutral Rating and $87 PT on Allergan 12/1/11

Disclosure Insight Maintains Medium Risk Rating on Allergan 11/17/11

UPDATE: Piper Jaffray Lowers PT to $87 on Allergan 10/27/11

Goldman Sachs Reiterates Buy on Allergan 10/27/11

Deutsche Bank Has Buy on Allergan 10/27/11

Piper Jaffray Lowers PT on Allergan to $87 10/27/11

End-of-Day Market Summary for October 26, 2011 10/26/11

J.P. Morgan Publishes 3Q/11 Preview on Specialty Pharmaceuticals 10/17/11

Trade AGN
NOW!

Partner Headlines

Gilead EPS Misses, Share Dip 2/2/12

AIDS-Fighter Gilead Misses EPS Views; Shares Dip Late 2/2/12

Allergan Q4 Earnings Meet, But Shares Fall On Outlook 2/2/12

Stocks Mixed, But Limited, Nu Skin Lead Breakouts 2/2/12

Earnings Beat for Allergan - Analyst Blog 2/2/12

Allergan Q4 Earnings Beat, But Shares Fall On Outlook 2/2/12

Gilead Stock, In Top Group, Slips Before Earnings 2/2/12

Earnings Preview: Allergan - Analyst Blog 1/31/12

UBS: 6 Specialty Pharma Picks to Watch 1/21/12

Solta's LIPOSONIX Reaches the U.S. - Analyst Blog 1/13/12

7 Stocks Set to Rise Above $100 in 2012 1/13/12

Press Releases

Critical Alerts For Google, Newmont Mining, Allergan, Walter Energy, and Finisar Released By Seven Summits Research 2/3/12 Newswire Story

Allergan Reports Fourth Quarter 2011 Operating Results 2/2/12 Business Wire Story

Fitch Affirms Alestra's IDRs at 'BB-'; Outlook Stable 1/12/12 Business Wire Story

THE Aesthetic Show(TM) Announces Open Submissions for Second Annual THE Aesthetic Awards(TM), Honoring the Best in Aesthetic Medicine 1/9/12 GlobeNewswire Story

Allergan Announces Quarterly Conference Call 1/6/12 Business Wire Story

Winners Announced at THE Aesthetic Awards(TM) Miami, Co-Presented by New You Magazine 11/20/11 GlobeNewswire Story

Actress Christina Hendricks Urges Women to Join Her in the Final Weeks of the LATISSE® Wishes Challenge to Increase Money Raised for the Make-A-Wish Foundation® from $390,000 to Campaign Goal of $500,000 11/9/11 Newswire Story

Oceana Therapeutics Announces Definitive Agreement to be Acquired by Salix Pharmaceuticals 11/8/11 Business Wire Story

ExonHit Extends Strategic Collaboration with Allergan 11/2/11 Business Wire Story

Award-winning Actress Courtney Thorne-Smith and Allergan, Inc. Reveal Changes in Women's Perceptions of BOTOX Cosmetic Over Nearly a Decade 10/6/11 Newswire Story

National Headache Foundation, HealthyWomen and Allergan Offer People Living With Chronic Migraine a Chance to "Rewrite Your Day" 9/21/11 Newswire Story

Allergan Reports Third Quarter 2011 Operating Results 8/30/11 Business Wire Story

Get the latest AGN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Allergan, Inc. stock price.

Allergan, Inc. by YCharts

Allergan (AGN) 87.58 0.52

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On AGN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social